M&T Bank Corp Buys 405 Shares of Natera, Inc. (NASDAQ:NTRA)

M&T Bank Corp raised its stake in Natera, Inc. (NASDAQ:NTRA) by 7.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,513 shares of the medical research company’s stock after buying an additional 405 shares during the period. M&T Bank Corp’s holdings in Natera were worth $699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its holdings in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after purchasing an additional 1,883,481 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after buying an additional 532,874 shares during the period. AQR Capital Management LLC grew its position in shares of Natera by 257.6% during the 2nd quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after buying an additional 469,327 shares in the last quarter. PointState Capital LP increased its stake in shares of Natera by 112.0% during the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock valued at $99,343,000 after buying an additional 413,468 shares during the period. Finally, Marshall Wace LLP raised its holdings in shares of Natera by 53.6% in the second quarter. Marshall Wace LLP now owns 958,383 shares of the medical research company’s stock valued at $103,783,000 after acquiring an additional 334,630 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Piper Sandler increased their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Sanford C. Bernstein upped their target price on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Leerink Partners lifted their price target on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their price objective on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $152.67.

Natera Stock Performance

Shares of Natera stock opened at $170.80 on Tuesday. The company has a 50 day moving average price of $144.87 and a 200 day moving average price of $125.09. The firm has a market capitalization of $22.55 billion, a P/E ratio of -97.05 and a beta of 1.63. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 52 week low of $57.22 and a 52 week high of $175.63.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.95) earnings per share. Sell-side analysts expect that Natera, Inc. will post -1.61 EPS for the current year.

Insiders Place Their Bets

In other Natera news, Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now directly owns 19,386 shares in the company, valued at approximately $3,073,262.58. The trade was a 10.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Rowan E. Chapman sold 1,767 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $170.24, for a total transaction of $300,814.08. Following the completion of the sale, the director now directly owns 6,202 shares in the company, valued at $1,055,828.48. This trade represents a 22.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 132,963 shares of company stock valued at $21,250,107. 7.60% of the stock is owned by company insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.